Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy
Sign Up to like & getrecommendations! Published in 2022 at "Oncoimmunology"
DOI: 10.1080/2162402x.2022.2077898
Abstract: ABSTRACT The past decades witnessed the clinical employment of targeted therapies including but not limited to tyrosine kinase inhibitors (TKIs) that restrain a broad variety of pro-tumorigenic signals. TKIs can be categorized into (i) agents… read more here.
Keywords: inhibitors tkis; kinase inhibitors; tyrosine kinase; trial watch ... See more keywords